COMBINATIONS OF TGFβ INHIBITORS AND CDK INHIBITORS FOR TREATMENT OF BREAST CANCER Russian patent published in 2022 - IPC A61K31/455 A61K31/519 A61K31/565 A61K45/06 A61P35/00 

FIELD: medicine.

SUBSTANCE: group of inventions relates to combination therapy for the treatment of cancer by administration of TGFβ inhibitor in a combination with CDK inhibitor. A method for the treatment of breast cancer is proposed, including administration to a patient who needs it of amount of 4-(2-(5-chlor-2-fluorophenyl)-5-isopropylpyridine-4-ylamino)-N-(1,3-dihydroxypropane-2)-yl)nicotineamide or its pharmaceutically acceptable salt and amount of Palbociclib or its pharmaceutically acceptable salt, where the specified amounts together provide an effect in the treatment of breast cancer. A method for the treatment of breast cancer is also proposed, including administration to a patient who needs it of amount of 4-(2-(5-chlor-2-fluorophenyl)-5-isopropylpyridine-4-ylamino)-N-(1,3-dihydroxypropane-2)-yl)nicotineamide or its pharmaceutically acceptable salt and amount of 6-(difluormethyl)-8-((1R,2R)-2-hydroxy-2-methylcyclopentyl)-2-(1-(methylsulfonyl)piperidine-4-ylamino)pyrido[2,3-d]pyrimidine-7(8H)-one or its pharmaceutically acceptable salt, where amounts taken together provide an effect in the treatment of breast cancer. Methods can additionally include administration of Fulvestrant.

EFFECT: use of the above-mentioned combinations provides improvement of combined methods for the treatment of breast cancer, including breast cancer resistant to CDK inhibitors.

12 cl, 7 dwg, 3 tbl, 2 ex